Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microwave ablation combined with adebrelimab with or without apatinib for advanced previously treated solid tumors
ChiCTR2400085195Phase 2Not yet recruiting
- Sponsor
- Beidahuang Group General Hospital
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of adebrelimab and Rivoceranib in non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) (2 arms), sponsored by Beidahuang Group General Hospital. Primary endpoint: Objective response rate. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
adebrelimabRivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400085195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085195.